Want help reviewing this study?
Study ID: NCT06821945. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT06821945
A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
A short description of this study’s research objective has not yet been verified.
Medication studyAges 19+South Korea
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: from 19 years. Other eligibility criteria apply.
- Listed locations
- Daegu, South Korea · Guri-si, South KoreaSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Registry last updated: · Record retrieved: . These dates do not confirm site availability.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 30, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- Boryung Pharmaceutical Co., Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- South Korea
- Age range
- Over 19 Years
- Official registry ID
- NCT06821945
- Official title
- A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
Recruitment & locations
RecruitingDaegu · Guri-si
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Boryung Pharmaceutical Co., Ltd, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including BR5402A, BR5402A-1, BR5402B, BR5402B-1, BR5402C, BR5402C-1, BR5402D and BR5402D-1.
Who can participate?
This study is for people with schizophrenia. Listed age limits: from 19 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT05995782
SAD and MAD Study Safety and Tolerability of FB418
The registry lists this study as recruiting. Study locations are listed in South Korea. Confirm recruitment at each site. It focuses on Schizophrenia.
RecruitingNCT05511363
KarXT for Schizophrenia
The registry lists this study as recruiting. Study locations are listed in the United States, in France, in the United Kingdom, ... Confirm recruitment at each site. It is testing KarXT for Schizophrenia.
RecruitingNCT06126224
KarXT for Schizophrenia
The registry lists this study as recruiting. Study locations are listed in the United States, in Canada, in the United Kingdom, ... Confirm recruitment at each site. It is testing KarXT for Schizophrenia.